Organon & Co | OGN - Actif À Court Terme





Actif À Court Terme Changement Date
Bristol-Myers Squibb USD 28.58B 1.37B 2026-06
Celltrion KRW 481.57B 10.97B 2026-03
Cspc Pharmaceutical CNY 22.25B 359.48M 2025-12
Deva Holding AS TRY 9.13B 1.61B 2023-09
Dianthus Therapeutics USD 897.54M 222.37M 2026-06
Divis Laboratories Ltd INR 110.96B 12.53B 2026-03
Gilead Sciences USD 12.53B 6.11B 2026-06
Glaxosmithkline GBP 17.76B 5.83B 2026-03
Kangmei Pharma CNY 6.8B 225.83M 2026-03
Knight Therapeutics CAD 394.84M 5.86M 2025-12
Laboratorios Farma EUR 509.33M 128.63M 2023-12
Malin Corporation EUR 62.6M 26.7M 2024-12
Medical Developments International AUD 33.75M 1.79M 2025-12
Merck USD 36.68B 1.66B 2026-06
Neuren Pharmaceuticals AUD 332.23M 11.98M 2025-12
Novartis USD 26.61B 3.85B 2026-03
Organigram Holdings CAD 250.09M 6.46M 2026-03
Organon & Co USD 5.11B 179M 2026-06
Ovoca Bio EUR 2.07M 510K 2025-12
Pharma Mar EUR 280.95M 7.5M 2026-06
Qiagen NV USD 1.66B 116.37M 2026-06
Sartorius EUR 1.64B 280M 2026-06
Sino Biopharmaceutical CNY 33.82B 9.13B 2025-06
Tilray USD 729.32M 28.18M 2025-09
Zealand Pharma A/S 15.02B 652.12M 2026-03